Academia Sinica Logo

Recent advances in computational design, directed evolution, and recombinant protein technology have opened new avenues for cancer therapy. Dr. Mou Yun and Dr. Jack Hu from the Institute of Biomedical Sciences have introduced a novel therapeutic protein named "STYMIE," designed to activate both cytotoxic T lymphocytes and natural killer (NK) cells within the tumor microenvironment. STYMIE comprises an enhanced superantigen, a computationally designed cytokine, and a tumor-targeting antibody. Their research demonstrates significant suppression of colorectal, breast, and lung cancers through systemic STYMIE treatment. Furthermore, the study elucidates the molecular mechanisms of superantigen-mediated T cell activation, highlighting CD2 and CD58 as primary ligands. This groundbreaking work, showcasing innovative principles in immune cell engager design, was published in Advanced Science on June 28, 2024.

Dr. Mou Yun passed away in August 2023. Future correspondence can be addressed to Dr. Jack Hu.